-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
In this 52-week study (also known as ELEVATE UC 52), patients treated with etrasimod achieved statistically significant co-primary endpoints of clinical remission at both weeks 12 and 52 compared with placebo Sexual improvement
This global phase 3, multicenter, randomized, double-blind, placebo-controlled study enrolled 433 patients with ulcerative colon who had failed or were intolerant to at least one prior conventional therapy, biologics, or Janus kinase (JAK) inhibitors.
The full results of the study will be used for scientific journal publication and reporting
Etrasimod is being developed by Arena Pharmaceuticals, which Pfizer recently completed its acquisition of, and Genting Xinyao acquired the exclusive rights to develop, manufacture and commercialize etrasimod from Arena in Greater China and South Korea in 2017
"We are delighted to see the positive top-line results of etrasimod again, which shows its promise as a best-in-class therapy